Glucagon derivatives with improved stability
The present invention relates to a novel glucagon derivative peptide, and a composition for preventing or treating hypoglycemia containing the novel glucagon derivative peptide as an active ingredient. The glucagon derivative according to the present invention has improved physical properties due to the change in isoelectric point (pI) while being capable of maintaining an activity on glucagon receptors, and thus can improve patient compliance when used as a hypoglycemic agent, and is also suitable for administration in combination with other anti-obesity agents. Accordingly, the glucagon derivative according to the present invention can be effectively used for the prevention and treatment of hypoglycemia and obesity.
1. A peptide comprising the amino acid sequence of the following General Formula 1:
(General Formula 1)
X1-X2-QGTF-X7-SDYS-X12-X13-X14-X15-X16-X17-X18-
X19-X20-X21-F-X23-X24-W-L-X27-X28-T
wherein, in General Formula 1,
X1 is desamino-histidine, N-dimethyl-histidine, β-hydroxyimidazopropionic acid, 4-imidazoacetic acid, β-carboxyimidazopropionic acid, tryptophan, tyrosine, or deleted;
X2 is α-methyl-glutamic acid, aminoisobutyric acid (Aib), D-alanine, glycine, Sar(N-methylglycine), serine, or D-serine;
X7 is threonine or valine;
X12 is lysine or cysteine;
X13 is tyrosine or cysteine;
X14 is leucine or cysteine;
X15 is aspartic acid, glutamic acid, or cysteine;
X16 is glutamic acid, aspartic acid, serine, α-methyl-glutamic acid, or cysteine;
X17 is aspartic acid, glutamic acid, lysine, arginine, serine, valine, or cysteine;
X18 is aspartic acid, glutamic acid, arginine, or cysteine;
X19 is alanine or cysteine;
X20 is lysine, glutamic acid, glutamine, aspartic acid, or cysteine;
X21 is aspartic acid, glutamic acid, valine, or cysteine;
X23 is valine or arginine;
X24 is valine, leucine, or glutamine;
X27 is isoleucine or methionine; and
X28 is arginine,
with the proviso that the amino acid sequence of General Formula 1 excludes SEQ ID NO: 1 and SEQ ID NO: 12.
2. The peptide of claim 1 , wherein, in the amino acid sequence of General Formula 1,
X1 is tryptophan, tyrosine, or deleted;
X2 is serine or aminoisobutyric acid (Aib);
X7 is threonine or valine;
X12 is lysine or cysteine;
X13 is tyrosine or cysteine;
X14 is leucine or cysteine;
X15 is aspartic acid or cysteine;
X16 is glutamic acid, aspartic acid, serine, or cysteine;
X17 is aspartic acid, glutamic acid, lysine, arginine, valine, or cysteine;
X18 is aspartic acid, glutamic acid, arginine, or cysteine;
X19 is alanine or cysteine;
X20 is lysine, glutamic acid, glutamine, aspartic acid, or cysteine;
X21 is aspartic acid, glutamic acid, valine, or cysteine;
X23 is valine or arginine;
X24 is valine, leucine, or glutamine;
X27 is isoleucine or methionine; and
X28 is arginine,
with the proviso that the amino acid sequence of General Formula 1 excludes SEQ ID NO: 1 and SEQ ID NO: 12.
3. A pharmaceutical composition comprising the peptide according to claim 2 as an active ingredient.
4. A composition, comprising the peptide according to claim 2 as an active ingredient.
5. The peptide of claim 1 , which comprises the amino acid sequence represented by SEQ ID NO: 16 or 17.
6. A pharmaceutical composition comprising the peptide according to claim 5 as an active ingredient.
7. A composition, comprising the peptide according to claim 5 as an active ingredient.
8. A pharmaceutical composition comprising the peptide according to claim 1 as an active ingredient.
9. The pharmaceutical composition according to claim 8 , further comprising a pharmaceutically acceptable carrier.
10. A composition, comprising the peptide according to claim 1 as an active ingredient.